Research
Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) and triple agonists (e.g., retatrutide) produce significantly greater reductions in body weight and HbA1c compared to selective GLP-1 receptor agonists or placebo in individuals with type 2 diabetes and obesity.
For individuals with obesity or type 2 diabetes, dual GIP/GLP-1 agonists like tirzepatide offer superior weight loss and blood sugar control compared to older GLP-1-only drugs. Treatment typically starts at a low dose (2.5 mg weekly) and increases gradually to 5, 10, or 15 mg to manage side effects. Clinical trials show up to 20% body weight reduction in non-diabetic obese adults over two years.
StrongSupportsVERY_HIGH confidence
Emerging evidence suggests that dual GIP/GLP-1 receptor agonists and triple GIP/GLP-1/glucagon receptor agonists provide beneficial metabolic effects in individuals with type 2 diabetes and obesity.
Why this rating
Supported by multiple Phase III clinical trials (SURPASS, SURMOUNT) with large sample sizes.
Source
Physiology and clinical applications of GIP
Shunsuke Yamane et al. · Endocrine Journal · 2025
narrative_reviewCited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →